1. Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer

3. Introduction

4. Regional Differences Use of CDK 4 and 6 Inhibitors

5. CDK 4 and 6 Inhibitors in Germany

6. CDK 4 and 6 Inhibitors in Spain

7. CDK 4 and 6 Inhibitors in Italy

8. Patient Case 1: First-Line ER-Positive MBC Rapidly Recurring on Adjuvant AI Therapy

9. Case Discussion

10. PALOMA-3: PFS

11. PFS Proportional Benefits by Different Variables in MONARCH 2 and MONARCH 3

12. MONARCH 2 and MONARCH 3 Subgroup Analysis Liver Metastases

13. Case Conclusion

14. Patient Case 2: First-Line ER-Positive MBC Rapidly Recurring on Adjuvant AI Therapy

15. Case Discussion

16. MONALEESA-7 Time to Response

17. Case Conclusion

18. Patient Case 3: First-Line ER-Positive Asymptomatic MBC

19. Case Discussion

20. FALCON Trial PFS With and Without Visceral Disease in ITT Population

21. MONALEESA-2 PFS

22. CDK 4 and 6 Inhibitors: Providing Therapeutic Benefit in Endocrine-Sensitive Population

23. CDK 4 and 6 Inhibitors in Elderly Patients

24. Patient Case 4: First-Line, ER-Positive, Asymptomatic MBC

25. Case Discussion

26. CDK 4 and 6 Inhibitors: Providing Therapeutic Benefit in Endocrine-Resistant Population

27. Patient Case 5: First-Line, ER-Positive, Asymptomatic MBC

28. Case Discussion

29. MONALEESA-7: PFS

30. PALOMA-3: Premenopausal Subgroup

31. MONARCH 2: Pre-Menopausal Subgroup Analysis

32. Concluding Remarks

33. Abbreviations